TracyRenee(Mcmillan)LuckhardtMD(She/Her)

Critical Care Medicine, Pleural Disease

Associate Professor, Medicine, University of Alabama at Birmingham School of Medicine

Dr. Luckhardt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

I am a board certified Pulmonary and Critical Care physician. I specialize in the diagnosis and treatment of Interstitial Lung Disease, including Idiopathic Pulmonary Fibrosis (IPF), ILD related to autoimmune disease and all other diffuse parenchymal disease. I am principal investigator on multiple industry-sponsored clinical trials in Interstitial Lung Disease.

University of MichiganFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2007
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2000 - 2004
LSU School of Medicine in ShreveportClass of 2000

PubMed

76 citations
Therapeutic Targeting of Src Kinase in Myofibroblast Differentiation and Pulmonary Fibrosis
Meng Hu, Pulin Che, Xiaosi Han, Guo-Qiang Cai, Gang Liu
The Journal of Pharmacology and Experimental Therapeutics. 2014-10-01
10 citations
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations.
Tejaswini Kulkarni, Vincent G. Valentine, Fei Fei, Thi K. Tran-Nguyen, Luisa D Quesada-Arias
Plos One. 2021-11-23
30 citations
Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients.
Tejaswini Kulkarni, Kaiyu Yuan, Thi K. Tran-Nguyen, Young-il Kim, Joao A. de Andrade
Plos One. 2019-10-04

The Summer Coronavirus Surge Has Started to Ebb, but Delta’s Danger RemainsAugust 19th, 2021
Precision Medicine: UAB Study Creates ‘Mini-Lung’ to Study Effect of Pulmonary Fibrosis DrugsJanuary 26th, 2017